

Tomasz Burzykowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8798242/publications.pdf>

Version: 2024-02-01

185
papers

8,566
citations

66315

42
h-index

49868

87
g-index

193
all docs

193
docs citations

193
times ranked

11138
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
2	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
3	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. <i>Lancet, The</i> , 2000, 356, 373-378.	6.3	395
4	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
5	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
6	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314
7	Linear Mixed-Effects Models Using R. <i>Springer Texts in Statistics</i> , 2013, , .	3.8	268
8	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
9	Validation of surrogate end points in multiple randomized clinical trials with failure time end points. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 405-422.	0.5	163
10	High prevalence of foot diseases in Europe: results of the Achilles Project. <i>Mycoses</i> , 2003, 46, 496-505.	1.8	162
11	Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. <i>Pharmaceutical Statistics</i> , 2006, 5, 173-186.	0.7	150
12	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology, The</i> , 2009, 10, 341-350.	5.1	138
13	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
14	Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 484-492.	0.8	133
15	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
16	Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3224-3229.	0.8	121
17	Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. <i>Cardiovascular Drugs and Therapy</i> , 1999, 13, 191-200.	1.3	120
18	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120

#	ARTICLE	IF	CITATIONS
19	Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas?. <i>Journal of Surgical Oncology</i> , 2002, 81, 63-69.	0.8	111
20	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002, 23, 607-625.	2.0	108
21	Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. <i>Journal of Clinical Oncology</i> , 2005, 23, 6139-6148.	0.8	107
22	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <i>Biometrical Journal</i> , 2016, 58, 104-132.	0.6	93
23	Evaluation of Normalization Methods to Pave the Way Towards Large-Scale LC-MS-Based Metabolomics Profiling Experiments. <i>OMICS A Journal of Integrative Biology</i> , 2013, 17, 473-485.	1.0	89
24	A statistical approach to central monitoring of data quality in clinical trials. <i>Clinical Trials</i> , 2012, 9, 705-713.	0.7	83
25	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Oncolmunology</i> , 2015, 4, e1026529.	2.1	79
26	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
27	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 7007-7013.	0.6	73
28	The isotopic distribution conundrum. <i>Mass Spectrometry Reviews</i> , 2012, 31, 96-109.	2.8	73
29	Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. <i>European Journal of Cancer</i> , 2006, 42, 1344-1350.	1.3	70
30	The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2004, 167, 103-124.	0.6	69
31	Design and Analysis of Drug Combination Experiments. <i>Biometrical Journal</i> , 2005, 47, 299-308.	0.6	68
32	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008, 17, 467-475.	0.7	65
33	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
34	Risk factors for bovine herpesvirus-1 seropositivity. <i>Preventive Veterinary Medicine</i> , 2005, 69, 285-295.	0.7	59
35	PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
36	Disease-free survival as a surrogate for overall survival in patients with <i>HER2</i> -positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370.	5.1	59

#	ARTICLE	IF	CITATIONS
37	Linear Mixed-Effects Model. Springer Texts in Statistics, 2013, , 245-273.	3.8	54
38	CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumor Biology, 2014, 35, 4619-4628.	0.8	50
39	Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints. Biometrics, 2004, 60, 724-728.	0.8	49
40	A perspective on surrogate endpoints in controlled clinical trials. Statistical Methods in Medical Research, 2004, 13, 177-206.	0.7	49
41	Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer, 2001, 34, S59-S64.	0.9	48
42	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. Biometrical Journal, 2002, 44, 921-935.	0.6	44
43	A model-based method for the prediction of the isotopic distribution of peptides. Journal of the American Society for Mass Spectrometry, 2008, 19, 703-712.	1.2	44
44	Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. European Respiratory Journal, 2001, 17, 660-666.	3.1	43
45	On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate Endpoints. Biometrics, 2015, 71, 15-24.	0.8	41
46	Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiotherapy and Oncology, 2002, 64, 281-290.	0.3	40
47	Simplified hierarchical linear models for the evaluation of surrogate endpoints. Journal of Statistical Computation and Simulation, 2003, 73, 643-658.	0.7	40
48	An Efficient Method to Calculate the Aggregated Isotopic Distribution and Exact Center-Masses. Journal of the American Society for Mass Spectrometry, 2012, 23, 753-763.	1.2	40
49	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. Journal of the National Cancer Institute, 2018, 110, 232-240.	3.0	40
50	BRAIN: A Universal Tool for High-Throughput Calculations of the Isotopic Distribution for Mass Spectrometry. Analytical Chemistry, 2013, 85, 1991-1994.	3.2	38
51	The effects of foot disease on quality of life: results of the Achilles Project. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 191-195.	1.3	37
52	Axillary Sentinel Node and Tumour-related Factors Associated with Non-sentinel Node Involvement in Breast Cancer. Japanese Journal of Clinical Oncology, 2004, 34, 519-524.	0.6	36
53	Computational methods and challenges in hydrogen/deuterium exchange mass spectrometry. Mass Spectrometry Reviews, 2017, 36, 649-667.	2.8	35
54	A Version of the EM Algorithm for Proportional Hazard Model with Random Effects. Biometrical Journal, 2005, 47, 847-862.	0.6	32

#	ARTICLE	IF	CITATIONS
55	Linear mixed-effects models for central statistical monitoring of multicenter clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 5265-5279.	0.8	32
56	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.4	30
57	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
58	Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 1998, 22, 191-200.	0.9	26
59	Choice of units of analysis and modeling strategies in multilevel hierarchical models. <i>Computational Statistics and Data Analysis</i> , 2004, 47, 537-563.	0.7	25
60	Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. <i>Journal of Applied Statistics</i> , 2003, 30, 235-247.	0.6	24
61	Testing for Trends in Dose-Response Microarray Experiments: A Comparison of Several Testing Procedures, Multiplicity and Resampling-Based Inference. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2007, 6, Article26.	0.2	23
62	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011, 55, 2748-2757.	0.7	23
63	Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 1998, 12, 1424-1428.	3.1	22
64	Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 773-783.	1.9	22
65	Missing data: Discussion points from the PSI missing data expert group. <i>Pharmaceutical Statistics</i> , 2010, 9, 288-297.	0.7	21
66	Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. <i>British Journal of Cancer</i> , 1996, 74, 956-960.	2.9	20
67	Using a Poisson approximation to predict the isotopic distribution of sulphur-containing peptides in a peptide-centric proteomic approach. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 3387-3391.	0.7	20
68	Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. <i>Journal of Neurology</i> , 2016, 263, 927-936.	1.8	20
69	Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. <i>Gastric Cancer</i> , 2016, 19, 24-30.	2.7	20
70	Comparison of different estimation procedures for proportional hazards model with random effects. <i>Computational Statistics and Data Analysis</i> , 2007, 51, 3913-3930.	0.7	19
71	Data-driven risk identification in phase III clinical trials using central statistical monitoring. <i>International Journal of Clinical Oncology</i> , 2016, 21, 38-45.	1.0	19
72	A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. <i>Statistical Methods in Medical Research</i> , 2010, 19, 205-236.	0.7	18

#	ARTICLE	IF	CITATIONS
73	Markers for nutrition studies: review of criteria for the evaluation of markers. <i>European Journal of Nutrition</i> , 2013, 52, 1685-1699.	1.8	18
74	Analysis of photon count data from single-molecule fluorescence experiments. <i>Chemical Physics</i> , 2003, 288, 291-307.	0.9	17
75	The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 432-449.	0.4	17
76	Applied Surrogate Endpoint Evaluation Methods with SAS and R. , 0, , .		17
77	Vegetables Affect the Expression of Genes Involved in Anticarcinogenic Processes in the Colonic Mucosa of C57Bl/6 Female Mice. <i>Journal of Nutrition</i> , 2005, 135, 1879-1888.	1.3	16
78	Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed!. <i>Journal of Clinical Oncology</i> , 2007, 25, 5673-5674.	0.8	15
79	Effect of the number of uninvolved nodes on survival in early breast cancer. <i>Oncology Reports</i> , 0, , .	1.2	15
80	Markov-Chain-Based Heteroscedastic Regression Model for the Analysis of High-Resolution Enzymatically ¹⁸ O-Labeled Mass Spectra. <i>Journal of Proteome Research</i> , 2010, 9, 2669-2677.	1.8	14
81	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. <i>Biometrics</i> , 2012, 68, 248-257.	0.8	14
82	Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. <i>Medicine (United States)</i> , 2015, 94, e853.	0.4	14
83	Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 1-11.	0.6	14
84	Surrogate endpoints: wishful thinking or reality?. <i>Statistical Methods in Medical Research</i> , 2008, 17, 463-466.	0.7	13
85	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522.	0.7	13
86	Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1682-1687.	0.8	12
87	An Investigation on Performance of Significance Analysis of Microarray (SAM) for the Comparisons of Several Treatments with one Control in the Presence of Small ² Variance Genes. <i>Biometrical Journal</i> , 2008, 50, 801-823.	0.6	12
88	A Nonhomogeneous Hidden Markov Model for Gene Mapping Based on Next-Generation Sequencing Data. <i>Journal of Computational Biology</i> , 2015, 22, 178-188.	0.8	12
89	An Information-Theoretic Approach for the Evaluation of Surrogate Endpoints Based on Causal Inference. <i>Biometrics</i> , 2016, 72, 669-677.	0.8	12
90	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1591-1594.	13.9	12

#	ARTICLE	IF	CITATIONS
91	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 170-183.	0.7	12
92	Multivariate Analysis of Risk Factors for Development of Duodenal Ulcer in <i>Helicobacter pylori</i> -Infected Patients. <i>Digestion</i> , 2003, 67, 25-31.	1.2	11
93	Vegetables Affect the Expression of Genes Involved in Carcinogenic and Anticarcinogenic Processes in the Lungs of Female C57Bl/6 Mice. <i>Journal of Nutrition</i> , 2005, 135, 2546-2552.	1.3	11
94	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	1.2	11
95	Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results. , 2018, 6, 134.		11
96	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627.	0.5	11
97	The retrospective study of 93 patients with transmigration of mandibular canine and a comparative analysis with a control group. <i>European Journal of Orthodontics</i> , 2019, 41, 390-396.	1.1	11
98	The effect of long-term water storage on the tensile strength of orthodontic brackets bonded with resin-reinforced glass-ionomer cements. <i>Journal of Orofacial Orthopedics</i> , 1999, 60, 361-370.	0.5	10
99	Design-based analysis of surveys: a bovine herpesvirus 1 case study. <i>Epidemiology and Infection</i> , 2003, 131, 991-1002.	1.0	10
100	A strategy for the prior processing of high-resolution mass spectral data obtained from high-dimensional combined fractional diagonal chromatography. <i>Journal of Mass Spectrometry</i> , 2009, 44, 516-529.	0.7	10
101	Simultaneous Mapping of Multiple Gene Loci with Pooled Segregants. <i>PLoS ONE</i> , 2013, 8, e55133.	1.1	10
102	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
103	Resampling Plans for Frailty Models. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2006, 35, 497-514.	0.6	9
104	Using Linear Mixed Models for Normalization of cDNA Microarrays. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2007, 6, Article 19.	0.2	9
105	A Cross-Validation Study to Select a Classification Procedure for Clinical Diagnosis Based on Proteomic Mass Spectrometry. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2008, 7, Article 12.	0.2	9
106	Reply to the Comment on:. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 1828-1829.	1.2	9
107	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	0.8	9
108	Fitting Linear Mixed-Effects Models: The lmer() Function. <i>Springer Texts in Statistics</i> , 2013, , 303-326.	3.8	8

#	ARTICLE	IF	CITATIONS
109	The use of the isotopic distribution as a complementary quality metric to assess tandem mass spectra results. <i>Journal of Proteomics</i> , 2014, 98, 150-158.	1.2	8
110	A hidden Markov-model for gene mapping based on whole-genome next generation sequencing data. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2015, 14, 21-34.	0.2	8
111	The search for surrogate endpoints for immunotherapy trials. <i>Annals of Translational Medicine</i> , 2018, 6, 231-231.	0.7	8
112	Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 399-400.	3.0	7
113	Pseudo-likelihood estimation for a marginal multivariate survival model. <i>Statistics in Medicine</i> , 2004, 23, 947-963.	0.8	7
114	Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 187-199.	1.2	7
115	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3744-3744.	0.6	7
116	Validation of Biomarkers as Surrogates for Clinical Endpoints. <i>Drugs and the Pharmaceutical Sciences</i> , 2003, , .	0.1	7
117	p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. <i>European Journal of Cancer Prevention</i> , 2000, 9, 81-88.	0.6	6
118	Performance of Gene Selection and Classification Methods in a Microarray Setting: A Simulation Study. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2008, 37, 409-424.	0.6	6
119	Differences in the Elemental Isotope Definition May Lead to Errors in Modern Mass-Spectrometry-Based Proteomics. <i>Analytical Chemistry</i> , 2015, 87, 10747-10754.	3.2	6
120	Estimation of Diagnostic Accuracy of a Combination of Continuous Biomarkers Allowing for Conditional Dependence Between the Biomarkers and the Imperfect Reference-Test. <i>Biometrics</i> , 2017, 73, 646-655.	0.8	6
121	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
122	De novo prediction of the elemental composition of peptides and proteins based on a single mass. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4367.	0.7	6
123	No association of leukemia inhibitory factor (LIF) DNA polymorphisms with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 171, 189-192.	1.1	5
124	A Markov-Chain Model for the Analysis of High-Resolution Enzymatically 18O-Labeled Mass Spectra. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2011, 10, Article 1.	0.2	5
125	Statistical Interaction in the Survival Analysis of Early Breast Cancer using Registry Data: Role of Breast Conserving Surgery and Radiotherapy. <i>Tumori</i> , 2005, 91, 9-14.	0.6	4
126	Fitting Conditional Survival Models to Meta-Analytic Data by Using a Transformation Toward Mixed-Effects Models. <i>Biometrics</i> , 2008, 64, 834-842.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Comparison of the Mahalanobis Distance and Pearson's χ^2 Statistic as Measures of Similarity of Isotope Patterns. Journal of the American Society for Mass Spectrometry, 2014, 25, 293-296.	1.2	4
128	Neoadjuvant as Future for Drug Development in Breast Cancer Letter. Clinical Cancer Research, 2016, 22, 268-268.	3.2	4
129	Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. JAMA Oncology, 2017, 3, 416.	3.4	4
130	Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints. Pharmaceutical Statistics, 2022, 21, 122-132.	0.7	4
131	The Detection of Metabolite-Mediated Gene Module Co-Expression Using Multivariate Linear Models. PLoS ONE, 2016, 11, e0150257.	1.1	4
132	Statistical analysis of data from single molecule experiment. , 2003, 5258, 171.		3
133	Finding Clusters of Positive and Negative Coregulated Genes in Gene Expression Data. , 2007, , .		3
134	A Bayesian Model Averaging Approach to the Quantification of Overlapping Peptides in an MALDI-TOF Mass Spectrum. International Journal of Proteomics, 2011, 2011, 1-14.	2.0	3
135	The correlation structure of longitudinal measurements of vision in patients with macular degeneration. Pharmaceutical Statistics, 2011, 10, 115-121.	0.7	3
136	Fitting Linear Mixed-Effects Models: The lme() Function. Springer Texts in Statistics, 2013, , 275-301.	3.8	3
137	Development of a diagnostic test based on multiple continuous biomarkers with an imperfect reference test. Statistics in Medicine, 2016, 35, 595-608.	0.8	3
138	Progression-free survival as surrogate endpoint of overall survival in patients with advanced/recurrent gastric cancer: Individual patient data analysis on 4,102 patients from 20 randomized trials.. Journal of Clinical Oncology, 2011, 29, 4095-4095.	0.8	3
139	An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. Oncotarget, 2017, 8, 17270-17278.	0.8	3
140	Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.. Journal of Clinical Oncology, 2017, 35, 766-766.	0.8	3
141	A Bayesian Markov-Chain-Based Heteroscedastic Regression Model for the Analysis of ^{18}O -Labeled Mass Spectra. Journal of the American Society for Mass Spectrometry, 2011, 22, 499-507.	1.2	2
142	A Markov-chain-based regression model with random effects for the analysis of ^{18}O -labelled mass spectra. Journal of Statistical Computation and Simulation, 2013, 83, 145-157.	0.7	2
143	The Analysis of Peptide-Centric Mass-Spectrometry Data Utilizing Information About the Expected Isotope Distribution. , 2017, , 45-64.		2
144	Sequential double cross-validation for assessment of added predictive ability in high-dimensional omic applications. Annals of Applied Statistics, 2018, 12, .	0.5	2

#	ARTICLE	IF	CITATIONS
145	Experimental Design in Quantitative Proteomics. <i>Methods in Molecular Biology</i> , 2019, 1977, 181-197.	0.4	2
146	Predicting the number of sulfur atoms in peptides and small proteins based on the observed aggregated isotope distribution. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e9162.	0.7	2
147	Semi-parametric accelerated failure-time model: A useful alternative to the proportional-hazards model in cancer clinical trials. <i>Pharmaceutical Statistics</i> , 2022, 21, 292-308.	0.7	2
148	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	0.8	2
149	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3578.	0.8	2
150	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
151	Predicted and observed thyroid cancer incidence in Poland after year 1986. <i>Wiadomości Lekarskie</i> , 2004, 57, 306-10.	0.1	2
152	The Use of Background Signal in the Transformation of cDNA-Microarray Measurements. <i>Applied Bioinformatics</i> , 2006, 5, 161-172.	1.7	1
153	Titrating <i>Theileria parva</i> : Single stocks against combination of stocks. <i>Experimental Parasitology</i> , 2008, 118, 522-530.	0.5	1
154	Simplified modeling strategies for surrogate validation with multivariate failure-time data. <i>Computational Statistics and Data Analysis</i> , 2010, 54, 1457-1466.	0.7	1
155	Evaluation of Laplace distribution-based ANOVA models applied to microarray data. <i>Journal of Applied Statistics</i> , 2011, 38, 937-950.	0.6	1
156	Genomic Biomarkers for a Binary Clinical Outcome in Early Drug Development Microarray Experiments. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 72-92.	0.4	1
157	Fitting Linear Models with Heterogeneous Variance: The <code>gls()</code> Function. <i>Springer Texts in Statistics</i> , 2013, , 149-158.	3.8	1
158	Linear Model with Fixed Effects and Correlated Errors. <i>Springer Texts in Statistics</i> , 2013, , 177-196.	3.8	1
159	Joint modelling of a binary and a continuous outcome measured at two cycles to determine the optimal dose. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 369-384.	0.5	1
160	A Bayesian Framework Allowing Incorporation of Retrospective Information in Prospective Diagnostic Biomarker-Validation Designs. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 311-323.	0.6	1
161	Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long-term clinical endpoint. <i>Pharmaceutical Statistics</i> , 2021, , .	0.7	1
162	PLS-SEM Mediation Analysis of Gene-Expression Data for the Evaluation of a Drug Effect. <i>Lecture Notes in Computer Science</i> , 2017, , 59-69.	1.0	1

#	ARTICLE	IF	CITATIONS
163	Phase II/III clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC).. Journal of Clinical Oncology, 2014, 32, 5555-5555.	0.8	1
164	Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis.. Journal of Clinical Oncology, 2015, 33, 10547-10547.	0.8	1
165	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. Journal of Clinical Oncology, 2015, 33, 666-666.	0.8	1
166	Factors associated with non-sentinel node involvement in breast cancer. European Journal of Cancer, Supplement, 2004, 2, 80.	2.2	0
167	A Modeling Approach to the Analysis of Nerve Regenerative Experiments. Journal of Biopharmaceutical Statistics, 2006, 16, 843-859.	0.4	0
168	A Comparison of Procedures for Controlling the False Discovery Rate in the Presence of Small Variance Genes: A Simulation Study. Communications in Statistics Part B: Simulation and Computation, 2009, 38, 2111-2122.	0.6	0
169	Data Exploration. Springer Texts in Statistics, 2013, , 39-65.	3.8	0
170	Linear Models with Homogeneous Variance. Springer Texts in Statistics, 2013, , 69-88.	3.8	0
171	Fitting Linear Models with Homogeneous Variance: The lm() and gls() Functions. Springer Texts in Statistics, 2013, , 89-111.	3.8	0
172	ARMD Trial: Linear Model with Heterogeneous Variance. Springer Texts in Statistics, 2013, , 159-173.	3.8	0
173	Linear Models with Heterogeneous Variance. Springer Texts in Statistics, 2013, , 123-147.	3.8	0
174	Fitting Linear Models with Fixed Effects and Correlated Errors: The gls() Function. Springer Texts in Statistics, 2013, , 197-212.	3.8	0
175	ARMD Trial: Modeling Correlated Errors for Visual Acuity. Springer Texts in Statistics, 2013, , 213-241.	3.8	0
176	PRT Trial: Modeling Muscle Fiber Specific-Force. Springer Texts in Statistics, 2013, , 385-430.	3.8	0
177	SII Project: Modeling Gains in Mathematics Achievement-Scores. Springer Texts in Statistics, 2013, , 431-463.	3.8	0
178	ARMD Trial: Modeling Visual Acuity. Springer Texts in Statistics, 2013, , 327-384.	3.8	0
179	FCAT Study: Modeling Attainment-Target Scores. Springer Texts in Statistics, 2013, , 465-489.	3.8	0
180	Extensions of theRTools for Linear Mixed-Effects Models. Springer Texts in Statistics, 2013, , 491-523.	3.8	0

#	ARTICLE	IF	CITATIONS
181	Surrogate end points: when should they be used?. <i>Clinical Investigation</i> , 2013, 3, 1147-1155.	0.0	0
182	Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD). <i>Breast</i> , 2017, 32, S26.	0.9	0
183	Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry. , 2010, , .		0
184	Abstract LB-004: Molecular hallmarks of cancer: Stemness. , 2017, , .		0
185	Relationship Among the Foraminal Area and Demographic and Clinical Characteristics of Patients with Low Back Pain. <i>World Neurosurgery</i> , 2022, 160, e520-e528.	0.7	0